Innosek Additive Manufacturing

brian.bischoff@innosek.com

High quality and consistent additive manufacturing at production volumes

I am a manufacturer offering space and production for COVID19 solutions

Free MATLAB software and technical support for any Startup working with a BiANYS Incubator or Accelerator

https://www.mathworks.com/

awillard@mathworks.com

MathWorks is the leading developer of mathematical computing software.
MATLAB, the language of engineers and scientists, is a programming environment for algorithm development, data analysis, visualization, and numeric computation.
Simulink is a block diagram environment for simulation and Model-Based Design of multidomain and embedded engineering systems. They can explore and implement designs without having to write C, C++, or HDL code.

I can offer technical assistance to companies solving COVID19 issues

omyst is a fully patented herbal first aid spray. It kills MRSA on contact and we hope to demonstrate that it also kill COVID 19 on contact as well.

I have a product for COVID19 related issues and need help connecting to government or end users

A 'big data'/machine learning approach to COVID-19 risk assessment and monitoring.

eugene@primediscoveries.com

Prime has developed the first COVID-19 RISK test that can be used to triage patients using biological risk scores rather than basic viral ID and has built multi-omics infrastructure to process hundreds of millions of samples. Founding team has worked closely together for 5 years - Chief Science Officer is from Genentech R&D where he led the analysis for the Immunochip Consortium, Founders built the core infrastructure for several genetic testing companies, one of which was acquired for $100 Million, are advised by Dr. George Church who invented sequencing and is a leading expert in multi-omics, and are funded by leading New York and Silicon Valley VC firms and angels including BoxGroup, Liquid 2 Ventures, New York University Venture Fund, Esther Dyson, Unshackled Ventures etc.

Prime will save millions of lives and mitigate the strain on the global healthcare systems by triaging patients by severity of COVID-19 infection.

Prime’s infrastructure and data can be used for shortening the path for vaccine development.

Team
Eugene Joseph, Founder & CEO, and Arun Manoharan, Founder & CSO, have built the genomics infrastructure for several computational genomics companies which were scaled to support hundreds of thousands of samples and patients.
Broad Experience:
CEO & CSO have worked together for 5 years building genomics products and infrastructure & CSO has previous experience as a member of Genentech’s R&D team. Founders have 20 years of combined experience in -omics.
CSO has experience developing high throughput assays including custom genotyping arrays, targeted and untargeted Next Generation Sequencing, RT-PCR and ddPCR assays, 16S and Shotgun microbiome sequencing and single-cell sequencing assays.
CSO has filed multiple patents on non-invasive PGS for embryo DNA testing, identifying copy number variants in human DNA using NGS and machine learning-based disease classification using microbiome sequencing.
Genentech R&D:
CSO was also part of the human genetics team at Genentech where he analyzed whole genomes, 247,000 rare variants using Illumina ExomeArray and 196,000 common variants in the HLA region using the Infinium Immunochip for >30,000 human subjects and initial analysis on 23&Me collaboration data, to identify causal variants in multiple autoimmune diseases including lupus, IBD, Alzheimer’s, Rheumatoid Arthritis, Asthma, and AMD.

Vision:
Developing Risk Scores for COVID-19 using Biological and Demographic Data
Biological Data
Molecular epidemiology, intervention/symptoms data, genomics, viral, etc.
Demographic data
Age, pre-existing conditions, longitudinal data, etc.
Reduce Case Curve & Build Dataset
Develop a large longitudinal dataset with millions of individuals that can be used to reduce the case curve and work with partner companies i.e. Genentech/Roche to use the dataset for the purposes of drug and vaccine development
Save Millions of Lives Globally
Triaging patients by severity of COVID-19 infection using multi-omics
Partner with Drug Developers, Synthetic Biology, and Sequencing Companies
Work with partners for access to sequencing/patient meta-data

Prime’s Infrastructure:
Coronavirus Genome Database
Built reference database and processed ~1,700 novel coronavirus full genomes from GISAID
Identification Capabilities
Custom coronavirus databases for quick alignment and identification
Cloud Processing in AWS
Fully automated cloud infrastructure which can process millions of samples
Identifying Key Regions
Working on the identification of key regions of the novel coronavirus genome which can be used to design fast PCR tests for identifying viral strains and source
Vaccine Development
Analyzing regions which can help narrow down targets for vaccines and setup automated leads for repurposing existing drugs (eg Actemra from Genentech)
Proprietary Dataset / Establishing Benchmarks
In discussions with sourcing samples which can be used for benchmarking our scoring methods and validation

Pipeline of Expertise:
We have spent the last two years indexing individuals sorted by expertise in the following key domain areas and know who needs to be involved across Hospitals, Scientific Research (Microbiome, Genomics, Synthetic Biology, Virology, etc.), AI, Government Agencies, NGOs, etc. This requires rapid hiring, implementation, and buildout.

Source of Funding:
Capital from Governments, Venture Firms, NGOs, High-Net-Worth Individuals

Prime’s Infrastructure:
Coronavirus Genome Database
Built reference database and processed ~1,700 novel coronavirus full genomes from GISAID
Cloud Processing in AWS
Fully automated cloud infrastructure which can process millions of samples
Identifying Key Regions
Working on the identification of key regions of the novel coronavirus genome which can be used to design fast PCR tests for identifying viral strains and source
Vaccine Development
Analyzing regions which can help narrow down targets for vaccines and setup automated leads for repurposing existing drugs (eg Actemra from Genentech)

I have a product for COVID19 and need technical assistance with production

we have the technology can convert CPAPs into invasive and non evasive ventilators.

Kbeck@ceoconnection.com

CPAP/BiPAP to PCV Ventilator

The CPAP/BiPAP-to-PCV Ventilator conversion kitwas designed specifically to help address the dire ventilator shortage due to the COVID-19 Pandemic. As of this writing, New York City is the current epicenter of this virus, and over 900 deaths were reported in the US within a 24 hour period. This indicates that the death rate in the US is currently doubling every three days - on par to quickly outpace even Italy, who was hit extremely hard a couple of weeks prior to the US.

It appears that the aside from the obvious calamity and complete lack of preparedness for such a widespread catastrophe, the primary mechanisms of death in the COVID-19 Pandemic will likely be due to:
• ARDS
• Lack of respiratory support (ventilators, respiratory therapists) to combat the influx of ARDS patients to the ICU
o Lack of PPE contributing to dwindling personnel

The lack of ventilators is a massive dilemma that boils down to a lack of parts/components, and a lack of supply chain to address the shortage quickly enough - especially for New York.

Our CPAP/BiPAP-to-PCV Ventilator conversion kit was designed to address these shortages. There is a massive supply and supply chain for CPAP/BiPAP machines prescribed for Sleep Apnea. These machines in their stock form do not have the capability of functioning as PCV Ventilators (aside from hospital-grade units), but they do have the necessary electromechanical components to function as such - and are already FDA approved medical devices. Our conversion kit utilizes the electromechanical components of the existing CPAP/BiPAP machines, and adds in a closed-loop pressure regulating control system, combined with a therapist-programmable interface to control ventilator mode (control or support mode), peak pressure, PEEP, Breathing rate (b/min), and Inspiratory/Expiratory ratio (I:E). This converts the device into a basic PCV Ventilator capable of supporting 30+ cmH2O of pressure, and a programmable PEEP with a high settable limit - with the understanding that ARDS patients need substantial PEEP to maintain alveoli recruitment and to prevent pneumothorax.

Another chief concern with such a conversion - especially in the case of non-invasive ventilation (NIV) - is the spread of aerosol or droplets from the open-loop circuits present in these CPAP/BiPAP machines. We have designed an anti-aerosolization system that utilizes existing standard parts, including exhaust ports and ViroBac II N95-grade inline filters. This ensures that absolutely minimal droplets escape the closed-loop system, even in NIV cases (of course, we recommend the added precaution of a surgical mask over the NIV mask in any case).

Lastly, this design was established to address this need in HIGH VOLUME. Using a small BOM of very easily obtainable parts (and parts that do not overlap with the existing invasive ventilator (IV) supply chain), virtually any existing supply of CPAP/BiPAP machines can be converted for immediate use as a basic PCV Ventilator.

I have a product for COVID19 related issues and need help connecting to government or end users

Applied DNA Sciences, Inc.

COVID-19 Diagnostic Kits and Vaccines from a linear DNA platform

https://adnas.com/linearx/

james.hayward@adnas.com

Applied DNA Sciences is in late pre-clinical trials of an RT-qPCR diagnostic assay that detects very low copy number of the COVID-19 infectious RNA, and is completing the manufacture of 5 candidate COVID-19 vaccines that will enter EU-approved animal studies this month. We are the leader in linear DNA-based therapeutics and diagnostics manufactured by large scale polymerase chain reaction. Linear DNA avoids the risk of traditional nucleic acid manufacture by bacterially-based plasmids. Our production methods are cleaner, faster, safer, and most rapidly modified in the event of a changing global healthcare condition. The Company provides linear DNA to approximately 20 large pharmaceutic and biotech companies already, and has a series of proprietary therapeutics and diagnostics. Our platform could be especially useful in the response to COVID-19.

Center for Biotechnology at Stony Brook University

diane.fabel@stonybrook.edu

I have a product for COVID19 related issues and need help connecting to government or end users

fmukhi@altimacareinc.com

We have created an incubator box that is reusable and able to get sterilized with a dish washer.

I have a product for COVID19 related issues and need help connecting to government or end users

fmukhi@altimacareinc.com

We have manufactured a reusable dishes washer safe face shield.

I have a product for COVID19 related issues and need help connecting to government or end users

Contract printed circuit boards, cables and electronic assembly. We can help companies from prototypes through to high volume production

I am a manufacturer offering space and production for COVID19 solutions

www.green-framework.com

Barbara Dutton-Weingarten

barbara@green-framework.com

Avast is a dry fog Misting Sterilizer which is used to aerosol Hydrogen peroxide solution of 7% in micron scale droplets in order to destroy viruses and other pathogens in domestic, medical and commercial environments.
The effectiveness of H2O2 on viruses has been recognized for over 100 years with large amounts data available to support this.
The dry mist fogger utilizes ultrasonic diaphragm ceramic discs to create a micro fine fog from the hydrogen peroxide solution. The liquid is aerosolized at a rate of 250 to 400 ml per hour.
Taking an average room size as 3 mtrs X 4 mtrs X 3 mtrs the volume of this room is 36 Cubic mtrs.
The recommended time for exposure of the AVAST operation in a room of this volume is 6 minutes which would deliver 25 – 40 ml of H2O2 solution into the 36 Cubic mtrs for a volume .69 mils to 1.11 mils per Cubic mtr of air space.
Given the volume of a micron diameter droplet size the number of droplets per cubic mtr in average the room will be 0.89 and 1.43 billion in the recommended time period. Random air movement will ensure contact with almost every area during the closed-up period following the use of the Avast system.
As has been proven in may papers, a H2O2 solution droplet that contacts a virus breaks down the Fatty protein external shell and destroys it.
A closed-up period of 30 minutes is recommended following the Dry fog application. This is followed by a complete airing of the room the remove any remaining airborne H2O2.
All people should be excluded for the sealed space during the sterilization process to avoid triggering any unintended respiratory or dermatological reactions.
The surface areas of the room is 66 square meters. This means that an even coating of the H2O2 solution would be .37 and .6 ml per square mtr of surface area and as such the surface will feel dry to the touch even directly after a complete application at room temperature.
The Avast unit is NOT FDA approved.
However going on data already generated by products developed in Italy and certified by ITEL (university of Barcelona) using the same method of dispersion for a 7% H2O2 solution it is expected that the same degree of success will be found by using the AVAST device.
In the case of the Infinity device (Italy) the Kill rate was found to be 99.99999% or Log 7.
Assessment is required to validate the expected efficacy of the Avast device.
Method:
1. Place a Petri dish or slide with a known count of the target Virus in an enclosed area of known volume.
2. Run the Avast device for the advised time per cubic meter of the known volume.
3. Allow the fog to remain in the sealed space for the 30-minute period.
4. Open the space and count the number of virus on the Petri dish or slide.
5. Compare the starting Virus count with the finished count.

If satisfactory kill rate is achieved Certify the Avast device for General use.

We are clients at CEBIP in SUNY Stony Brook but this is not related to clean energy

I have a product for COVID19 related issues and need help connecting to government or end users

Quadrant Biosciences Inc

richard.uhlig@quadrantbiosciences.com

Rapid and more accurate COVID-19 molecular diagnostic (developed in partnership with SUNY Upstate Medical University)

https://www.quadrantbiosciences.com/

richard.uhlig@quadrantbiosciences.com

"Clarifi COVID-19" is a rapid, more efficient and more accurate molecular assay than those currently available for the clinical detection of a COVID-19 viral infection. This multiplexed test uses qPCR equipment that is already resident in nearly all clinical laboratories. Quadrant intends to commercialize 96- and 384-well PCR reaction plates pre-filled with mastermix, primers and probes; these can be rapidly manufactured and distributed. Substantial research and development has been underway for weeks in the SUNY Molecular Analysis CORE facility; we intend to submit an Emergency Use Authorization (EUA) application to the FDA within the next 5 business days.

I have a product for COVID19 related issues and need help connecting to government or end users

REVITALE Pharma Limited

Repruposed product for treatment and prevention of COVID-19

jjseman@revitalepharma.com

The new coronavirus SARS-CoV-2 (COVID-19) has mutation in the spike glycoprotein that introduced a new Furin cleavage site (http://www.virology.ws/2020/02/13/furin-cleavage-site-in-the-sars-cov-2-coronavirus-glycoprotein/). Human Furin in the respiratory tract plays a role in cutting proteins to make them active. A virus takes advantage of Furin and other human proteases to cut the viral proteins into a form recognized by human cells, so the virus is internalized. This new mutation allows SARS-CoV-2 to infect humans.

We have a product that has demonstrated the ability to inhibit furin based on in-vitro and in-vivo studies. The product is FDA approved and we are seeking to repurpose the drug for treating and preventing COVID-19.

phuong.t.nguyen@stonybrook.edu

I have a product for COVID19 related issues and need help connecting to government or end users

Sanatela Life Sciences, Inc.

michaelcrowley@sanatelamedical.com

We are ready, willing and able to produce trillions of pluripoten stem cells for treatment that should gain FDA fast track approval very soon. These are rare cells from healthy live births needed in the billions of cells per patient treatment. The FDA applicant is aware of our capability to pivot to producing these cells by openning our new 20k sq ft lab in Rochester, NY. We obtain these cells as a part of our decellurization of wharton's jelly tissue to create our 3D bio-engineered matrix being commercialized with worldwide exclusive license from U of R IP (patent pending). We have everything ready to begin process except the funding to acquire some needed equipment and working capital. Once approved this treatment will save lives and the lungs by the millions as the virus continues to attack the US and global citizens. We have a ready supply of umbilical cords ready to go each day we need them from the hospital maternity wards. We have 12 wet labs ready to go and have the staff ready to go to get the cells and culture them as required. We are prepared fully to be FDA GMP compliant on day one. We need about $50-70k per lab for off-the-shelf equipment needed to start withing about 30 days.

https://erincrowley60.wixsite.com/website-2

michaelcrowley@sanatelamedical.com

Please first see our Wefunder Fight the Virus site for more information

https://wefunder.com/sanatelalifesciencesinc

Our product is pluripotent stem cells, also sometimes referred to as Mesenchymal stem cells (MSCs), which are are multipotent stromal cells that can differentiate into a variety of cell types, including osteoblasts (bone cells), chondrocytes (cartilage cells), myocytes (muscle cells) and adipocytes (fat cells which give rise to marrow adipose tissue). These stem cells, injected by the billions into severe pneumonia patients from Covid-19 can treat and potentially cure this pneumonia.

Clinical trials are progressing well. Now at Phase 2 with 250 patients on fast track FDA plan of attack. Already approved for compassionate care and emergency care by FDA as result of trials completed to date. We have been asked to gear-up our labs to decellurize Wharton's jelly, the source of the cells, and culture the cells we harvest over a period of several days into many many billions of cells per cord.

Each treatment will required billions of cells. We have the personnel and capacity required to product trillions of cells needed for treatments for US and worldwide.

We are in the process of raising $10 million in capital to begin full production of the Sanatela Matrix that will be used for cancer screening and allow oncologist to undertake in vitro in the lab individualized cancer stem cell treatments targeted to kill Cancer Stem Cells. see www.sanatelamedical.com for explainer video on home page.

We are willing to pivot to focus more upon culturing the MSCs for treatment purposes. We need only get capital, we are ready to go in all other respects.

Many very prominent physicians and researchers are working with us on this project - and they believe that this is the treatment that will save lungs and lives until a vaccine is produced many months into the future.

Nextcorp in Rochester, University of Rochester, RIT

Erin Daly Hunt <admin@bianys.com>

I have been asked to ramp-up production at our new labs to accommodate Covid-19 treatment & cure for severe pneumonia using billions of pluripotent stem cells harvested and cultured from Wharton's jelly within umbilical cord tissue. Treatment is at Phase 2 trial - approved already for emergency use and compassionate care.

Hands-free smart-glasses Telehealth platform optimizes provider to provider communication, integrate into bedside workflow and utilization to provide expertise/help when needed while minimizing exposure and save on PPE.

https://OpticSurgInc.com/CovidZero/

Our hands-free smart-glasses Telehealth platform optimizes provider to provider communication, integrate into bedside workflow and utilization to provide expertise/help when needed while minimizing exposure and save on PPE. The technology empowers people to be where they need to be (virtually) and see what they need to see and resultedly provide short term and long term value improving patient care.

I have a product for COVID19 related issues and need help connecting to government or end users

Direct testing for the detection of the SAR-COVD2 (COVID 19) virus as well as antibodies

bill.phelan@flurotest.com

FluroTest believes it can develop direct tests for SARS-CoV-2 and IgG/IgM antibodies. We are employing two well accepted technologies, fluorescence detection and biochemistry (dye labelling and antibody/virus binding). Developed correctly, these tests could provide quantitative values with excellent specificity and sensitivity in under 5 minutes. FluroTest considers that quantitative results will provide better understanding of the disease and potentially aid in prescribed treatments.

I have a product for COVID19 related issues and need help connecting to government or end users

dan@seatswaptickets.com

NowAware is a rapid covid test that instantly changes colors in the presence of an enzyme specifically secreted by the Coronavirus without the need for lab, specialized equipment or scarce reagents. Because it's a simple chemistry-based test, it can scale up to millions of tests produced per day in a short period of time.

I have a product for COVID19 related issues and need help connecting to government or end users

VISUALC3 provides a wealth of notification, verification, dispatch, and response tools that improve security, enhance communications, and provide a unique level of situational awareness.

Stacey.Sikes@hofstra.edu

I have a product for COVID19 related issues and need help connecting to government or end users

The containment of infectious diseases has become the focus of worldwide efforts during and post COVID-19. Aeragen, an NYU spin-out with an exclusive license on the patent, is developing a first of its kind personal containment chamber. AirVENT, the company’s first product, takes the concept of expensive negative pressure rooms and scaling down to individual users with a simple, portable, pre-clinically validated solution that can re-enable medical procedures, save critical healthcare dollars and improve workplace safety for EMTs, doctors, nurses, and staff.

I have a product for COVID19 related issues and need help connecting to government or end users

Software coupled with heat-sensitive cameras which provide a solution for mass screening on those entering buildings.

www.buffautomation.com

Vikram@buffautomation.com

Buffalo Automation is leveraging its expertise gained over several years developing AI to
interpret thermal images captured by vehicles. Bifrost, our advanced and highly-trained neural
network, can extract human features from a given image and measure skin temperatures only
from areas that are most likely to indicate fever, while simultaneously adjusting for changing
patterns in ambient thermal conditions.

I have a product for COVID19 related issues and need help connecting to government or end users

Novel best in class air filtration for personal and industrial applications.

A sleek, crystal clear swivel-down full-face visor and halo unit connected via discreet silicon tubes to a small, patented, air compressor housed in a rechargeable hip unit that filters 99.95% of all particulates through an H13 class HEPA filter and yet is sleek and unobtrusive allowing for a range of normal motion and activity (as well as facial hair). The airflow comes through tunes within the visor and out through a circle of perforations into the inside of the shield )not the outside). The airflow is strong enough to push out any ambient air present so you are left with an invisible bubble of safe air to breathe. We think this unit ups the ante for what PPE can be and how it can start to cross over into wearable technology. We also think it has the potential to reopen global economies and that many private industries As well as individuals will be grateful to invest in large contracts and have solutions planned for children, athletes, baby carriages as well as a line of similarly themed products and accessories to follow.

Phil Rugile of Launchpad Huntington

phil@launchpadhuntington.com

I have a product for COVID19 related issues and need help connecting to government or end users

just incorporated, no website yet

Iodine has been shown to kill many pathogens in vitro and on skin surfaces. Even most doctors do not know that it is safe on mucosal surfaces. (Ophthalmologists like me have used it for years on conjunctiva.) I cured my own corona with vaporized iodine and have since filed 3 patents on use, methods, formulation, dosage, use with complementary drugs, use with respirators, etc., and incorporated a company to bring it to market. I have started assembling a team. The current challenge is finding a partnership with a medical center to do an initial clinical trial to corroborate my findings independently.

I have a product for COVID19 related issues and need help connecting to government or end users

lwetzel@airinnovations.com

IsolationAir is a portable HVAC unit that can convert an ordinary hospital room into a negative or positive pressure isolation room. Isolation Rooms in hospitals are normally built specifically for positive or negative pressure uses and therefore are restricted in their use. When patients with COVID-19 hit the emergency rooms, there were not enough negative pressure rooms available to contain the virus being transmitted by the occupant and potentially spreading thru-out the hospital. With an IsolationAir unit, the hospital could safely isolate the infected patient in an ordinary room.

Ed Bogucz, former ExDir Syracuse Center of Excellence

I have a product for COVID19 related issues and need help connecting to government or end users

Smartphone-integrated virus sensing elements paired with contactless access control to ensure a virus-free common space

Matthew Jacobs, D.O. - Founder & CEO, Chief Resident - Psychiatry, Stony Brook Medicine

matthew.jacobs@viralforecast.io

Viral Forecast is dedicated to the highest quality of virus detection and safety delivered with originality, creativity and imagination. We have emerged from the Front Lines to take on the COVID-19 Pandemic by way of global force & interdisciplinary collaboration. Our mindful approach integrates viral sensing elements with smartphones and contactless access control to ensure a virus-free common space, to help facilitate a swift recovery and prevent future like Pandemics.

Center for Biotechnology - Stony Brook University

heather.bielski@stonybrook.edu

I have a product for COVID19 and need technical assistance with production